XTL Biopharmaceuticals (XTLB) Stock Analysis

What XTL Biopharmaceuticals does

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.

Key metrics

ETFs linked to XTLB

Broad-market and Healthcare sector ETFs an investor holding XTL Biopharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how XTLB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for XTL Biopharmaceuticals?

XTL Biopharmaceuticals trades under the ticker XTLB on NASDAQ.

Which exchange is XTLB listed on?

XTLB is listed on NASDAQ.

What sector does XTL Biopharmaceuticals operate in?

XTL Biopharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze XTLB in a portfolio?

PortView shows XTLB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.